You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The approach allows researchers to profile the protein complexes present in a sample in much the same way they have the individual peptides and proteins.
The researchers presented new reagents and software for de novo peptide sequencing, an emerging technology with potential in proteomics and biopharma.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
Driven by strong pharma sales, revenues increased to $715 million from $687 million in Q4 2017, besting the consensus analyst estimate of $703 million.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
The resource provides a look at protein localization patterns across the proteome as well as responses to events like alternative splicing and drug perturbation.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
The team compiled these proteins in three panels that could help researchers better assess plasma sample quality in protein biomarker work.
The company is currently using the model, named EDGE, in its own personalized cancer vaccine work and in collaboration with outside immunotherapy developers.
Researchers at the University of Copenhagen used mass spectrometry to analyze dental plaque from 21 individuals recovered from a medieval Danish gravesite.
Revenues in the third quarter grew to $466.6 million from $335.6 million in Q3 2017, beating the consensus Wall Street estimate of $451.7 million.
New work has looked at how common HLA peptide splicing is, which has significance for immunotherapy and infectious disease research.
The company reported $5.92 billion in revenues for the quarter, driven by growth across its four business segments.
Agena has an ongoing partnership with Guangzhou-based DaRui to develop MassArray-based diagnostics for cancer and inherited diseases for the Chinese market.
The company's revenues were up, but fell short of Wall Street estimates as growth in the European market was hampered by lower sales to pharma customers there.
The approach could be particularly useful for harmonizing data from large multi-site efforts as proteomics experiments continue to grow in size and complexity.
A preliminary analysis based on high-resolution metabolomics pointed to three blood plasma metabolites with apparent ties to active, pulmonary tuberculosis.
The tool allows users to search for unexpected modifications and other phenomena that are difficult to identify using conventional mass spec search software.
The scientists developed a metabolomic panel capable of predicting BMI and identifying subsets of at-risk patients with apparently healthy BMIs.
A team from the EPFL has identified the chemical NTCB as a potential digestion reagent for middle-down work, though bioinformatic hurdles still remain.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.